Epigenetics in lung fibrosis: From pathobiology to treatment perspective

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 5, 2015, Pages 454-462

  Helling, Britney A ^a   Yang, Ivana V ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Global Health and Health Disparities   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

Author keywords

DNA methylation; Gene regulation; Histone modifications; Pulmonary fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYCLOOXYGENASE 2; DESMOPLAKIN; FAS ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; HISTONE DEACETYLASE INHIBITOR; MUCIN 5B; PROTEIN BAK; PROTEIN BCL XL; PROTEIN P14; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TOLL LIKE RECEPTOR 9; VORINOSTAT;

CELL PROLIFERATION; CPG ISLAND; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; EPIGENETICS; FIBROSING ALVEOLITIS; GENE CONTROL; GENE EXPRESSION; GENE LOCUS; HISTONE MODIFICATION; HUMAN; REVIEW; ANIMAL; GENETIC EPIGENESIS; GENETIC VARIATION; GENETICS; GENOMICS; PATHOLOGY;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC VARIATION; GENOMICS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS;

EID: 84942935542     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000191     Document Type: Review

References (132)

1. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013; 5:483-492.
2. Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176:277-284.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-2092.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071-2082.
5. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345:517-525.
6. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378:1949-1961.
7. Boucher RC. Idiopathic pulmonary fibrosis - A sticky business. N Engl J Med 2011; 364:1560-1561.
8. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364:1503-1512.
9. Yang IV, Fingerlin TE, Evans CM, Schwarz MI, DA S. MUC5B and idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2015 (in press).
10. Rock JR, Barkauskas CE, Cronce MJ, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesench-ymal transition. Proc Natl Acad Sci USA 2011; 108:E1475-E1483.
11. Yang IV, Coldren CD, Leach SM, et al. Expression ofcilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 2013; 68:1114-1121.
12. Vaughan AE, Brumwell AN, Xi Y, et al. Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury. Nature 2015; 517:621-625.
13. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesench-ymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005; 166:1321-1332.
14. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006; 103:13180-13185.
15. Tanjore H, Xu XC, Polosukhin VV, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 2009; 180:657-665.
16. Farkas L, Gauldie J, Voelkel NF, Kolb M. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 2011; 45:1-15.
17. Fattman CL. Apoptosis in pulmonary fibrosis: too much or not enough? Antioxid Redox Signal 2008; 10:379-385.
18. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3:350-356.
19. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009; 15:1077-1081.
20. Tanjore H, Cheng DS, Degryse AL, et al. Alveolar epithelial cells undergo epithelial-to-mesenchymal transition in response to endoplasmic reticulum stress. J Biol Chem 2011; 286:30972-30980.
21. Lawson WE, Cheng DS, Degryse AL, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA 2011; 108:10562-10567.
22. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104:7552-7557.
23. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105:13051-13056.
24. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178:729-737.
25. Chilosi M, Doglioni C, Murer B, Poletti V. Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27:7-18.
26. Scotton CJ, Krupiczojc MA, Konigshoff M, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009; 119:2550-2563.
27. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med 2008; 5:e62.
28. King T, Costabel U, Cordier J-F, et al. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161 (2 Pt 1):646-664.
29. Kaminski N. Microarray analysis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29 (3 Suppl):S32-S36.
30. Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 180:167-175.
31. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PloS One 2007; 2:e482.
32. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006; 173:188-198.
33. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002; 99:6292-6297.
34. Boon K, Bailey NW, Yang J, et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PloS One 2009; 4:e5134.
35. Yang IV, Burch LH, Steele MP, et al. Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med 2007; 175:45-54.
36. Zhang Y, Noth I, Garcia JG, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med 2011; 364:1576-1577.
37. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68:436-441.
38. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013; 45:613-620.
39. Noth I, Zhang Y, Ma S-F, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Resp Med 2013; 1:309-317.
40. Borie R, Crestani B, Dieude P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PloS One 2013; 8:e70621.
41. Wei R, Li C, Zhang M, et al. Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes. Transl Res 2014; 163:494-502.
42. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185:67-76.
43. Gharib SA, Altemeier WA, Van Winkle LS, et al. Matrix metalloproteinase-7 coordinates airway epithelial injury response and differentiation of ciliated cells. Am J Respir Cell Mol Biol 2013; 48:390-396.
44. Allis CD, Jenuwein T, Reinberg D, editors. Epigenetics. New York: Cold Spring Harbor Laboratory Press; 2009.
45. Yang IV, Schwartz DA. Epigenetic control of gene expression in the lung. Am J Respir Crit Care Med 2011; 183:1295-1301.
46. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28:1057-1068.
47. Branco MR, Ficz G, Reik W. Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev Genet 2012; 13:7-13.
48. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447:433-440.
49. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4:143-153.
50. Doi A, Park IH, Wen B, et al. Differential methylation of tissue-and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009; 41:1350-1353.
51. Ji H, Ehrlich LI, Seita J, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010; 467:338-342.
52. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13:484-492.
53. Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012; 44:1236-1242.
54. Yang X, Han H, De Carvalho DD, et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 2014; 26:577-590.
55. Arrowsmith CH, Bountra C, Fish PV, et al. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012; 11:384-400.
56. Tarakhovsky A. Tools and landscapes of epigenetics. Nat Immunol 2010; 11:565-568.
57. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13:343-357.
58. Rivera CM, Ren B. Mapping human epigenomes. Cell 2013; 155:39-55.
59. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005; 102:10604-10609.
60. Heyn H, Li N, Ferreira HJ, et al. Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci USA 2012; 109:10522-10527.
61. Ong ML, Holbrook JD. Novel region discovery method for Infinium 450K DNA methylation data reveals changes associated with aging in muscle and neuronal pathways. Aging Cell 2014; 13:142-155.
62. Issa JP. Aging and epigenetic drift: a vicious cycle. J Clin Invest 2014; 124:24-29.
63. Selman M, Pardo A. Stochastic age-related epigenetic drift in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190:1328-1330.
64. Sarter B, Long TI, Tsong WH, et al. Sex differential in methylation patterns of selected genes in Singapore Chinese. Hum Genet 2005; 117:402-403.
65. Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006; 38:1378-1385.
66. El-Maarri O, Becker T, Junen J, et al. Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. Hum Genet 2007; 122:505-514.
67. Boks MP, Derks EM, Weisenberger DJ, et al. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PloS One 2009; 4:e6767.
68. Cotton AM, Lam L, Affleck JG, et al. Chromosome-wide DNA methylation analysis predicts human tissue-specific X inactivation. Hum Genet 2011; 130:187-201.
69. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006; 3:293-298.
70. Seibold MA, Schwartz DA. The lung: the natural boundary between nature and nurture. Annu Rev Physiol 2011; 73:457-478.
71. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007; 8:253-262.
72. Wan ES, Qiu W, Baccarelli A, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet 2012; 21:3073-3082.
73. Philibert RA, Sears RA, Powers LS, et al. Coordinated DNA methylation and gene expression changes in smoker alveolar macrophages: specific effects on VEGF receptor 1 expression. J Leukoc Biol 2012; 92:621-631.
74. Breitling LP, Yang R, Korn B, et al. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet 2011; 88:450-457.
75. Tennis MA, Vanscoyk MM, Wilson LA, et al. Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in nonsmall cell lung cancer. PloS One 2012; 7:e32921.
76. Buro-Auriemma LJ, Salit J, Hackett NR, et al. Cigarette smoking induces small airway epithelial epigenetic changes with corresponding modulation of gene expression. Hum Mol Genet 2013; 22:4726-4738.
77. Chen D, Fang L, Li H, et al. Cigarette smoke component acrolein modulates chromatin assembly by inhibiting histone acetylation. J Biol Chem 2013; 288:21678-21687.
78. Liu F, Killian JK, Yang M, et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 2010; 29:3650-3664.
79. Nagathihalli NS, Massion PP, Gonzalez AL, et al. Smoking induces epithelial-to-mesenchymal transition in nonsmall cell lung cancer through HDAC-mediated downregulation of E-cadherin. Mol Cancer Ther 2012; 11:2362-2372.
80. Mathai SK, Schwartz DA, Warg LA. Genetic susceptibility and pulmonary fibrosis. Curr Opin Pulm Med 2014; 20:429-435.
81. Abramowitz LK, Bartolomei MS. Genomic imprinting: recognition and marking of imprinted loci. Curr Opin Genet Dev 2012; 22:72-78.
82. Bell JT, Pai AA, Pickrell JK, et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol 2011; 12:R10.
83. Zhang D, Cheng L, Badner JA, et al. Genetic control of individual differences in gene-specific methylation in human brain. Am J Hum Genet 2010; 86:411-419.
84. Gibbs JR, van der Brug MP, Hernandez DG, et al. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet 2010; 6:e1000952.
85. Kasowski M, Kyriazopoulou-Panagiotopoulou S, Grubert F, et al. Extensive variation in chromatin states across humans. Science 2013; 342:750-752.
86. Kilpinen H, Waszak SM, Gschwind AR, et al. Coordinated effects of sequence variation on DNA binding, chromatin structure, and transcription. Science 2013; 342:744-747.
87. McVicker G, van de Geijn B, Degner JF, et al. Identification of genetic variants that affect histone modifications in human cells. Science 2013; 342:747-749.
88. Turner BM. Defining an epigenetic code. Nat Cell Biol 2007; 9:2-6.
89. Marconett CN, Zhou B, Rieger ME, et al. Integrated transcriptomic and epigenomic analysis of primary human lung epithelial cell differentiation. PLoS Genet 2013; 9:e1003513.
90. Hagood JS, Ambalavanan N. Systems biology of lung development and regeneration: current knowledge and recommendations for future research. Wiley Interdiscip Rev Syst Biol Med 2013; 5:125-133.
91. Morrisey EE, Cardoso WV, Lane RH, et al. Molecular determinants of lung development. Ann Am Thorac Soc 2013; 10:S12-S16.
92. Coward WR, Watts K, Feghali-Bostwick CA, et al. Defective histone acet-ylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol 2009; 29:4325-4339.
93. Coward WR, Feghali-Bostwick CA, Jenkins G, et al. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. FASEB J 2014; 28:3183-3196.
94. Coward WR, Watts K, Feghali-Bostwick CA, et al. Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idio-pathic pulmonary fibrosis. Mol Cell Biol 2010; 30:2874-2886.
95. Sanders YY, Tollefsbol TO, Varisco BM, Hagood JS. Epigenetic Regulation of Thy-1 by Histone Deacetylase Inhibitor in Rat Lung Fibroblasts. Am J Respir Cell Mol Biol 2011; 45:16-23.
96. Sanders YY, Pardo A, Selman M, et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008; 39:610-618.
97. Cisneros J, Hagood J, Checa M, et al. Hypermethylation-mediated silencing of p14(ARF) in fibroblasts from idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303:L295-303.
98. Hu B, Gharaee-Kermani M, Wu Z, Phan SH. Epigenetic regulation of myofibroblast differentiation by DNA methylation. Am J Pathol 2010; 177:21-28.
99. Hu B, Gharaee-Kermani M, Wu Z, Phan SH. Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis. Am J Pathol 2011; 178:1500-1508.
100. Dakhlallah D, Batte K, Wang Y, et al. Epigenetic Regulation of miR-17 ~92 Contributes to the Pathogenesis of Pulmonary Fibrosis. Am J Respir Crit Care Med 2013; 187:397-405.
101. Huang SK, Scruggs AM, Donaghy J, et al. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death Dis 2013; 4:e621.
102. Sanders YY, Hagood JS, Liu H, et al. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice. Eur Respir J 2014; 43:1448-1458.
103. Sanders YY, Liu H, Liu G, Thannickal VJ. Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence. Free Radic Biol Med 2015; 79:197-205.
104. Hogaboam CM, Murray L, Martinez FJ. Epigenetic mechanisms through which Toll-like receptor-9 drives idiopathic pulmonary fibrosis progression. Proc Am Thorac Soc 2012; 9:172-176.
105. Warburton D, Shi W, Xu B. TGF-beta-Smad3 signaling in emphysema and pulmonary fibrosis: an epigenetic aberration of normal development? Am J Physiol Lung Cell Mol Physiol 2013; 304:L83-L85.
106. Rabinovich EI, Kapetanaki MG, Steinfeld I, et al. Global methylation patterns in idiopathic pulmonary fibrosis. PloS One 2012; 7:e33770.
107. Sanders YY, Ambalavanan N, Halloran B, et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:525-535.
108. Huang SK, Scruggs AM, McEachin RC, et al. Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. PloS One 2014; 9:e107055.
109. Yang IV, Pedersen BS, Rabinovich E, et al. Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190:1263-1272.
110. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178-186.
111. Helling BA, Steele MP, Brown KK, et al. A common MUC5B promoter polymorphism (rs35705950) and risk of interstitial lung disease. Am J Respir Crit Care Med 2013; 187:A3815.
112. Thurman RE, Rynes E, Humbert R, et al. The accessible chromatin landscape of the human genome. Nature 2012; 489:75-82.
113. Roadmap Epigenomics Consortium. Kundaje A, Meuleman W, et al. Inte-grative analysis of 111 reference human epigenomes. Nature 2015; 518:317-330.
114. Wang J, Zhuang J, Iyer S, et al. Factorbook.org: a Wiki-based database for transcription factor-binding data generated by the ENCODE consortium. Nucleic Acids Res 2013; 41 (Database issue):D171-D1 76.
115. Gerstein MB, Kundaje A, Hariharan M, et al. Architecture of the human regulatory network derived from ENCODE data. Nature 2012; 489:91-100.
116. Wang J, Zhuang J, Iyer S, et al. Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res 2012; 22:1798-1812.
117. Vincent A, Perrais M, Desseyn JL, et al. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene 2007; 26:6566-6576.
118. Perrais M, Pigny P, Buisine MP, et al. Aberrant expression of human mucin gene MUC5B in gastric carcinoma and cancer cells. Identification and regulation of a distal promoter. J Biol Chem 2001; 276:15386-15396.
119. de Bustros A, Nelkin BD, Silverman A, et al. The short arm of chromosome 11 is a 'hot spot' for hypermethylation in human neoplasia. Proc Natl Acad Sci USA 1988; 85:5693-5697.
120. Park SH, Kim SK, Choe JY, et al. Hypermethylation of EBF3 and IRX1 genes in synovial fibroblasts of patients with rheumatoid arthritis. Mol Cells 2013; 35:298-304.
121. Yang L, Chen Y, Cui T, et al. Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/beta-catenin signaling pathway in human lung cancer. Carcinogenesis 2012; 33:1863-1870.
122. Yu DH, Waterland RA, Zhang P, et al. Targeted p16Ink4a epimutation causes tumorigenesis and reduces survival in mice. J Clin Invest 2014; 124:3708-3712.
123. Kaminskas E, Farrell AT, Wang YC, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005; 10:176-182.
124. Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007; 3:807-817.
125. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage Ilung cancer. N Engl J Med 2008; 358:1118-1128.
126. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced nonsmall cell lung cancer. Cancer Discov 2011; 1:598-607.
127. Konermann S, Brigham MD, Trevino AE, et al. Optical control of mammalian endogenous transcription and epigenetic states. Nature 2013; 500:472-476.
128. Di Ruscio A, Ebralidze AK, Benoukraf T, et al. DNMT1-interacting RNAs block gene-specific DNA methylation. Nature 2013; 503:371-376.
129. Heller EA, Cates HM, Pena CJ, et al. Locus-specific epigenetic remodeling controls addiction-and depression-related behaviors. Nat Neurosci 2014; 17:1720-1727.
130. Huffman K, Martinez ED. Pre-Clinical Studies of Epigenetic Therapies Targeting Histone Modifiers in Lung Cancer. Front Oncol 2013; 3:235.
131. Tang X, Peng R, Phillips JE, et al. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. Am J Pathol 2013; 183:470-479.
132. Davies ER, Haitchi HM, Thatcher TH, et al. Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 46:687-694.